

# CMC STRATEGY FORUM

ADVANCING BIOPHARMACEUTICAL DEVELOPMENT

## NORTH AMERICA 2024



### KNOWLEDGE SHARING AND CAPACITY BUILDING

- Despite the diversity of bioconjugates, the *challenges are largely the same across products*, e.g. stability, manufacturing, and analytics.
- The diversity of bioconjugates and limited regulatory guidance necessitates *early and proactive engagement* with Health Authorities.
- Even for mature modalities, there is *no categorical approach* – it *requires data-driven conversations* between reviewers and sponsors.
- Implementing state-of-the-art analytical technologies is *critical for the success* of the next generation of bioconjugates.

### CMC STRATEGY FORUM NORTH AMERICA 2024 BY THE NUMBERS



**First-Time Attendees**

**38**



**Regulators Participated**

**16**



**Companies Represented**

**41**



**Countries Collaborated**

**4**

Canada | Germany | Japan | United States

